RBC Capital Reiterates Outperform on Abbott Laboratories, Maintains $125 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Shagun Singh has reiterated an Outperform rating on Abbott Laboratories (NYSE:ABT) and maintained a price target of $125.
June 04, 2024 | 1:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Shagun Singh has reiterated an Outperform rating on Abbott Laboratories and maintained a price target of $125.
The reiteration of an Outperform rating and a maintained price target of $125 by RBC Capital is a positive signal for investors, suggesting confidence in Abbott Laboratories' future performance. This is likely to have a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100